Introduction {#S0001}
============

The risk of pre-term birth (PTB) associated with the use of protease inhibitors (PIs) in pregnancy remains the subject of intense debate. While a number of studies from Europe have found an increased risk of PTB associated with PI use \[[@CIT0001]--[@CIT0004]\], until recently these findings have not been replicated in North American cohort studies \[[@CIT0005]--[@CIT0009]\], or in a meta-analysis on the subject \[[@CIT0010]\]. The conflicting reports and the difficulties in establishing such an association are in part due to the heterogeneity of comparison groups (comparing PI use to no treatment and or multiple different treatments), heterogeneity of populations studied and multiple confounders that have been inconsistently adjusted for in previous studies \[[@CIT0011]--[@CIT0013]\]. As a result, the question as to a link on PI use and prematurity remains unresolved, and in the absence of definitive evidence to support or refute this potential association, North American guidelines continue to recommend PI-based combination antiretroviral therapy (cART) as the preferred treatment of HIV-1-positive women during pregnancy \[[@CIT0014]\].

The use of PIs during pregnancy has changed significantly over time, as newer drugs were approved for use in HIV-positive pregnant women, and data became available on their safety and efficacy in preventing vertical transmission. Nelfinavir (NFV) was the preferred PI in pregnancy until 2006, due to its tolerability and low side-effect profile \[[@CIT0015]\]. This changed abruptly in 2007 after NFV was recalled from both United States and European markets for concerns regarding the presence of a potential carcinogenic element, ethyl methanesulfonate (EMS) in its formulation \[[@CIT0016]\]. Ritonavir-boosted lopinavir (LPV/r) then became the preferred PI used in pregnancy \[[@CIT0017]\], and NFV, even after safety issues regarding EMS were resolved, became an "alternative" choice to be used under special circumstances \[[@CIT0018]\]. These changes were reflected in prescribing patterns in both North America and Europe, with an increased use of LPV-r as the preferred PI for the treatment of HIV-positive pregnant women after 2007 \[[@CIT0019]\].

Previous studies on PTB have generally considered PIs as a single group for comparison against no treatment, non-nucleoside reverse transcriptase inhibitor (NNRTI) or nucleoside reverse transcriptase inhibitor (NRTI) based regimens, not distinguishing whether they were used with or without ritonavir (RTV) boosting \[[@CIT0020]\]. However, RTV, used individually or as a boosting agent, has its own unique side-effect profile. It is a potent inhibitor of cytochrome CYP3A4, which is implicated in the regulation of the adrenal axis \[[@CIT0021]\]. Fetal signals coming from the hypothalamic--pituitary--adrenal axis are suspected to play a fundamental role in the initiation of spontaneous labour, through elevations in cortisol levels associated with progesterone withdrawal and prostaglandin formation \[[@CIT0022]\]. Transient adrenal dysfunction has been reported in neonates exposed to LPV-r *in utero* and after birth \[[@CIT0023]\]. Thus, given RTV\'s potential impact on PTB through both the fetal and maternal adrenal systems, and the shift to RTV-boosted PIs in pregnancy after 2007, the primary objective of this study was to assess the risk of PTB associated with RTV boosting in pregnancy, in a single centre North American setting.

Methods {#S0002}
=======

Study population {#S0002-S20001}
----------------

This was a retrospective study using data from the Centre Maternel et Infantile sur le SIDA (CMIS) mother--child cohort. The CMIS cohort was established in 1988 to follow all HIV-positive pregnant women presenting to Centre Hospitalier Universitaire (CHU) Sainte-Justine, a tertiary referral centre in the city of Montreal, and the largest maternal--child health centre in the province of Quebec, Canada. HIV-positive pregnant women who consented to the cohort were prospectively followed during pregnancy, and their infants until age 18, to monitor for effects from *in utero* antiretroviral (ARV) drug exposure. The study was approved by the ethics committee of the CHU Sainte-Justine research centre.

Inclusion criteria for this study were: 1) attendance for at least two antenatal obstetric visits and 2) singleton live births, at 24 weeks of gestational age or older. Two antenatal visits (at minimum) were required to ensure that the patients included in the study were those engaged in care at CHU Sainte-Justine, thereby excluding those who presented only at delivery. ARV use during pregnancy was categorized into groups defined by the last ARV regimen used during pregnancy, as follows: 1) RTV-boosted PI-based regimen: LPV/r, atazanavir (ATV/r), tipranivir (TPV/r) or fosamprenavir (FPV/r) with two NRTIs; 2) unboosted PI-based regimen: NFV, indinavir (IDV) or saquinavir (SQV) with two NRTIs; 3) NNRTI based (nevirapine with 2 NRTIs); 4) NRTI based: zidovudine (AZT) monotherapy, AZT and lamividune (3TC) or triple combination NRTI; and 5) no treatment (no ARVs used at any time during pregnancy). ARV therapy during pregnancy was initiated after completion of the first trimester in treatment naïve patients, and adjusted for treatment-experienced patients according to standard North American guidelines. Additional variables studied included maternal CD4 count nearest to the time of delivery (measured by flow cytometry, up to 1 week before or 1 week after delivery), hepatitis C status (determined by hepatitis C antibody testing during pregnancy) and ethnicity, characterized as Caucasian, Black or other (mixed, First Nations, Latino or Asian).

Statistical analysis {#S0002-S20002}
--------------------

The association between maternal risk factors and PTB was assessed using odds ratios, and multivariable logistic regression was used to adjust for potential confounders identified in the study population and from the literature (maternal age, delivery CD4 count, parity, hepatitis C co-infection and ethnicity). PTB was defined as delivery at less than 37 completed weeks gestational age, determined by best estimates (self-reported date of last menstrual period, ultrasound-data). The multivariable analysis was restricted to only those women with complete data on all variables assessed. Goodness of fit of the final model was assessed using likelihood ratio (LR), and a generalized estimating equation (GEE) was applied to account for repeat pregnancies. All statistical tests were 2-sided and significance was set at *p*\<0.05. The analysis was conducted using SAS statistical software, version 9.3 (SAS Institute, Cary, NC).

Results {#S0003}
=======

Between 1988 and 2011, 705 women were enrolled in the CMIS cohort, among whom 589 met the study\'s inclusion criteria (19 were excluded due to twin gestation, 28 due to therapeutic or spontaneous abortion, and 69 due to only one visit on record). Overall, during the entire study period, unboosted PI-based cART was used in 220 (37.4%) women, RTV-boosted PI-based cART in 144 (24.4%), NNRTI- or NRTI-based cART (other) in 166 (28.1%), while 59 (10.0%) women received no treatment. Among boosted PIs, the most commonly used was LPV/r (81.2%), followed by ATV/r (13.4%), FPV/r (2.7%) and TPV/r (2.7%). Among unboosted PIs, the most commonly used was NFV (82.4%), followed by IDV (9.2%) and SQV (8.4%). The most common NRTI combinations used as a backbone regimen included AZT/3TC (63.0%), followed by abacavir (ABC)/3TC (4.9%), tenofovir (TDF)/emtricitrabine (FTC) (2.3%), stavudine (d4T) based (d4T/3TC or D4T/TDF) (2.3%) and didanosine based (ddI/3TC, ddI/AZT, ddI/3TC or ddI/TDF) (1.6%) and other (0.8%). A single NRTI (AZT) was used in 15.1% of women, while 10% received no treatment.

Characteristics of the women according to the type of ARV therapy received are summarized in [Table 1](#T0001){ref-type="table"}.

###### 

Maternal characteristics by treatment group

  Maternal characteristics   *N*   Boosted PI   Unboosted PI   Other        None        *p* ^[a](#TF0001){ref-type="table-fn"}^   *p* ^[b](#TF0002){ref-type="table-fn"}^
  -------------------------- ----- ------------ -------------- ------------ ----------- ----------------------------------------- -----------------------------------------
  Year of delivery                                                                                                                
   1988--1996                107   0 (0)        0 (0)          59 (35.5)    48 (81.4)   \<0.001                                   \<0.001
   1997--2006                318   18 (12.5)    196 (89.1)     97 (58.4)    7 (11.9)                                              
   2007--2011                164   126 (87.5)   24 (10.9)      10 (6.0)     4 (6.8)                                               
  Age (years)                                                                                                                     
    \< 25                    72    9 (6.3)      24 (11.0)      22 (13.3)    17 (29.3)   \<0.001                                   0.13
   25--35                    367   86 (59.7)    137 (62.8)     108 (65.5)   36 (62.1)                                             
    \> 35                    146   49 (34.0)    57 (26.2)      35 (21.2)    5 (8.6)                                               
  CD4 count (cells/mm^3^)                                                                                                         
    \< 200                   58    16 (11.9)    18 (8.6)       18 (11.2)    6 (11.3)    0.18                                      0.58
   200--350                  101   19 (14.2)    33 (15.8)      40 (24.8)    9 (17.0)                                              
    \> 350                   398   99 (73.9)    158 (75.6)     103 (64.0)   38 (71.7)                                             
  Parity                                                                                                                          
   Multip with PPTD          7     4 (2.8)      1 (0.45)       1 (0.6)      1 (1.7)     \<0.001                                   \<0.001
   Multip without PPTD       107   47 (32.9)    35 (15.9)      22 (13.3)    3 (5.1)                                               
   Nulliparous               474   92 (63.3)    184 (83.6)     143 (86.1)   55 (93.2)                                             
  Hepatitis C                                                                                                                     
   Negative                  557   135 (93.8)   201 (91.4)     163 (98.2)   58 (98.3)   0.015                                     0.40
   Positive                  32    9 (6.25)     19 (8.64)      3 (1.70)     1 (1.69)                                              
  Race                                                                                                                            
   Black                     379   103 (79.2)   130 (62.8)     108 (65.9)   38 (64.4)   \<0.001                                   0.006
   Caucasian                 140   20 (15.4)    58 (28.0)      42 (25.6)    20 (33.9)                                             
   Other                     41    7 (5.40)     19 (9.2)       14 (8.54)    1 (1.70)                                              

Chi-square test across all categories

Chi-square test comparing only boosted to unbooted PIs.

There were significant differences in the use of boosted versus unboosted PIs according to study time period, parity and ethnicity. The use of boosted PIs increased in the period from 2007--2011 as compared to 1997--2006 (87.5% vs. 12.5%, *p*\<0.001) with a corresponding decrease in the use of unboosted PIs during that time period (89.1% vs. 10.9%, *p*\<0.001). A larger proportion of nulliparous women were treated with unboosted versus boosted PIs (83.6% vs. 63.3%, *p*\<0.001), and a larger proportion of Caucasian women received unboosted versus boosted PIs (28.0 vs. 15.4%, *p*=0.007).

Risk of PTB {#S0003-S20001}
-----------

The risk of PTB according to maternal characteristics is summarized in [Table 2](#T0002){ref-type="table"}. The overall risk of PTB in our cohort was 13.5%. In the unadjusted analysis, the use of boosted PI regimens was associated with a significantly increased risk of PTB compared to non-boosted PI regimens (OR 2.01, 95% CI 1.02--3.97), while no increased risk was observed with the use of NNRTI/NRTI-based regimens as compared to non-boosted PI-based therapy (OR 0.81, 95% CI 0.40--1.66). The highest risk of PTB was seen among women receiving no ARV treatment when compared to unboosted PIs (OR 2.70, 95% CI 1.20--6.09). Among boosted PIs, the highest risk of PTB was among ATZ/r-treated women (*n*=20) (30%), followed by LPV/r (*n*=91) (18.7%), with no cases of PTB seen among TPV/r (*n*=4) or FPV/r (*n*=4) treated women. These differences were not statistically significant (*p*=0.33). Among unboosted PIs, the highest risk of PTB was among NFV-treated women (*n*=161) (11.8%), followed by IDV (*n*=18) (11.1%) and SQV (*n*=16) (6.3%). These differences were not statistically significant (*p*=0.83). Among NRTI backbone combinations used, there was no increased risk of PTB when comparing 3TC-, ddI- or d4T-based regimens to AZT monotherapy. Other significant risk factors associated with PTB on univariate analysis included parity \[multiparous with a history of previous pre-term delivery (PPTD) vs. nulliparous, OR: 15.19, 95% CI 1.85--125.8\], and hepatitis C co-infection (OR: 3.20, 95% CI 1.25--8.19).

###### 

Maternal characteristics and risk of pre-term delivery

  Predictor variable        Pre-term *N* (%)   Term *N* (%)   Unadjusted OR                                          *p*     Adjusted OR          *p*
  ------------------------- ------------------ -------------- ------------------------------------------------------ ------- -------------------- -------
  Total                     71 (13.5)          454 (86.5)                                                                                         
  Year of delivery                                                                                                                                
   1988--1996               17 (16.8)          84 (83.2)      1.05 (0.48--1.48)                                      0.9                          
   1997--2006               34 (11.6)          259 (88.4)     0.73 (0.38--1.38)                                      0.33                         
   2007--2011               20 (15.3)          111 (84.7)     1                                                                                   
  Age (years)                                                                                                                                     
    \> 35                   15 (11.8)          112 (88.2)     0.91 (0.35--1.63)                                      0.84    0.71 (0.27--1.87)    0.49
   25--35                   47 (14.2)          285 (85.8)     1.09 (0.48--1.52)                                      0.82    0.98 (0.45--2.15)    0.97
    \< 25                   9 (13.8)           56 (86.2)      1                                                              1                    
  ART treatment                                                                                                                                   
   No treatment             13 (25.0)          39 (75.0)      2.70 (1.20--6.09)                                      0.017   1.50 (0.33--6.78)    0.60
   NRTI/NNRTI               14 (8.8)           145 (91.2)     0.81 (0.40--1.66)                                      0.56    0.67 (0.27--1.63)    0.37
   Boosted                  23 (19.3)          96 (80.7)      2.01 (1.02--3.97)                                      0.045   2.17 (1.05--4.51)    0.038
   Unboosted                21 (10.8)          174 (89.2)     1                                                              1                    
  NRTI backbone                                                                                                                                   
   None                     13 (25.5)          38 (74.5)      2.59 (1.04--6.42)                                      0.041   1.40 (0.26--7.59)    0.69
   AZT/3TC                  37 (11.5)          285 (88.5)     1.12^[a](#TF0003){ref-type="table-fn"}^ (0.53--2.35)   0.44    0.50 (0.18--1.36)    0.17
   Tdf/3TC                  4 (33.3)           8 (66.7)                                                                                           
   ABC/3TC                  5 (20.0)           20 (80.0)                                                                                          
   D4T base                 1 (8.3)            11 (91.7)      0.42^[b](#TF0004){ref-type="table-fn"}^ (0.05--3.67)   0.77    0.20 (0.02--1.86)    0.16
   DDI base                 0 (0.0)            8 (100.0)                                                                                          
   Other                    1 (25.0)           3 (75.0)       2.67 (0.21--38.56)                                     0.44    1.59 (0.08--33.3)    0.77
   AZT                      9 (11.7)           68 (88.3)      1                                                                                   
  CD4 count (cells/mm^3^)                                                                                                                         
    \< 200                  6 (11.1)           48 (88.9)      0.68 (0.27--1.73)                                      0.43    0.59 (0.22--1.57)    0.29
   200--350                 8 (8.3)            88 (91.7)      0.50 (0.24--1.07)                                      0.07    0.56 (0.26--1.19)    0.13
    \> 350                  57 (15.2)          318 (84.8)     1                                                              1                    
  Parity                                                                                                                                          
   Multip with PPTD         3 (75.0)           1 (25.0)       15.19 (1.85--125.8)                                    0.012   13.28 (1.89--93.5)   0.009
   Multip without PPTD      16 (17.4)          76 (82.6)      1.64 (0.86--3.04)                                      0.12    1.56 (0.81--3.01)    0.18
   Nulliparous              52 (12.1)          377 (87.9)     1                                                              1                    
  Hepatitis C                                                                                                                                     
   Positive                 7 (33.3)           14 (66.7)      3.20 (1.25--8.19)                                      0.015   4.66 (1.71--12.75)   0.003
   Negative                 64 (12.7)          440 (87.3)     1                                                              1                    
  Race                                                                                                                                            
   Black                    48 (13.3)          312 (86.7)     1.01 (0.54--1.87)                                      0.40    1.49 (0.71--3.15)    0.29
   Other                    7 (18.4)           31 (81.6)      1.49 (0.59--3.79)                                      0.97    3.27 (1.16--9.16)    0.025
   Caucasian                16 (12.6)          111 (87.4)     1                                                              1                    

Combined OR for AZT/3TC, Tdf/3TC, ABC/3TC backbones

Combined OR for d4T- and DDI-based backbones.

The multivariable analysis was restricted to only those women with complete data on all variables assessed, and after excluding those women with missing data on the following variables (age=4, delivery CD4 count=23, ethnicity=35 and parity=2), this analysis was conducted on 525 of the 589 patients. The association between type of PI (boosted vs. unboosted) and risk of PTB remained significant after adjusting for maternal age, delivery CD4 count, parity, hepatitis C status and ethnicity (aOR 2.17, 95% CI 1.02--4.51). Other significant risk factors remained parity (multiparous with a history of PTB vs. nulliparous, aOR 13.28, 95% CI 1.89--93.5) and hepatitis C co-infection (OR: 4.66, aOR 1.71--12.75).

Discussion {#S0004}
==========

In this single centre retrospective study, we identified a number of risk factors for PTB among HIV-positive women delivering in Canada, including type of antiretroviral therapy (ART), previous history of PTB, and hepatitis C co-infection. While untreated HIV infection is a well-known risk factor for PTB \[[@CIT0024]\], among women treated with ART, we found an increased risk of PTB among those who received boosted versus unboosted PI-based regimens during pregnancy (aOR 2.04, 95% CI 1.02--4.14). Our findings of increased PTB associated with RTV boosting are consistent emerging findings from both developed and developing world settings. A study by the Agence Nationale de Recherche sur le Sida (ANRS) of France showed an increased rate of PTB among women treated with boosted versus unboosted PI (aHR 2.03, 95% CI 1.06--3.89), more specifically with respect to spontaneous delivery \[[@CIT0025]\]. Our PTB rate of 19.3% among women treated with boosted PIs is also similar to that found in the Mma Bana study (21.4%) from Botswana, where all women in the PI treated arm received LPV-r during pregnancy \[[@CIT0026]\]. In light of previous conflicting reports between North American and European cohorts, the concordance of our findings to the French perinatal cohort is reassuring.

In the present study, the use of unboosted PIs was not associated with an increased risk of PTB compared to NRTI- or NNRTI-based regimens. Interestingly, in a subset of previous studies (including one from our own centre) in which the type of PI used was reported, no association between PI use and PTB was seen in studies where NFV was reported as the primary PI used \[[@CIT0007],[@CIT0027]--[@CIT0029]\], while those in which LPV/r was used preferentially have demonstrated an increased risk of PTB \[[@CIT0009],[@CIT0025],[@CIT0027]\]. We hypothesize that in the majority of studies conducted prior to 2007, unboosted PIs may have been used preferentially, thereby explaining the lack of association seen with PIs and PTB in these earlier studies. Subsequent attempts at pooling the data, considering boosted and unboosted PIs together, may have contributed to the conflicting results.

While the mechanisms underlying the potential association between RTV boosting and PTB have yet to be fully understood, there is increasing evidence that maternal and fetal adrenal dysfunction from RTV exposure may play a role in the initiation of PTB. Progesterone is a sex hormone essential for the maintenance of pregnancy, and in a mouse pregnancy model, mice exposed to PIs during pregnancy were shown to have lower progesterone levels, more pregnancy loss, less viable pups per litter, and lower fetal and placental weights compared to mice exposed only to double NRTI therapy; among the PIs studied, RTV had the strongest inhibitory effect on progesterone levels in the mouse model \[[@CIT0030]\]. Lower levels of progesterone among RTV-treated women, something not assessed in the present study, may in part explain the higher rate of PTB among them. Moreover, transient fetal adrenal dysfunction from post-natal RTV exposure has been reported in a cohort of HIV-exposed uninfected newborns, with increased 17-hydroxy progesterone and dehydroepiandrosterone sulfate (DHEA-S) concentrations among newborns who received LPV-r prophylaxis compared to newborn treated with other ARV agents in the neonatal period \[[@CIT0023]\]. Given that fetal signals coming from the hypothalamic--pituitary--adrenal axis play a fundamental role in the initiation of spontaneous labour \[[@CIT0031]\], we suspect that transient fetal adrenal dysfunction from *in utero* RTV exposure may further contribute to the initiation of PTB.

The major limitations of our study are its retrospective nature, and our inability to adjust for other potential confounders. Due to the changing nature of the HIV epidemiology in our cohort over time, there were significant differences in maternal characteristics according to the type of PI treatment received. Nulliparous women were more likely to have received unboosted PIs, possibly reflecting first pregnancies among the first wave of prenatally infected women to have been followed and treated with ARVs. Caucasian women were also more likely to have received unboosted rather than boosted PIs, likely reflecting the increasing number of women diagnosed with HIV through immigration, compared to IV drug use or blood transfusion \[[@CIT0032],[@CIT0033]\]. While these were adjusted for in the multivariable analysis, we were unable to adjust for maternal weight gain during pregnancy, hard drug and alcohol use, and smoking. We were also unable to control for the timing of ARV initiation, which has been reported to influence PTB \[[@CIT0001],[@CIT0034],[@CIT0035]\]. Finally, we do not have information on mode of delivery, and of what proportion of pre-term births were iatrogenic caesarean section versus spontaneous PTB, which is an important consideration in the aetiology of PTB.

Given these limitations, our findings of increased risk of PTB among women treated with boosted PIs should be interpreted with caution. The success of cART in reducing mother-to-child transmission rates is a tremendous achievement, and cART remains the cornerstone of prevention. Nonetheless, in light of increased morbidity and mortality from prematurity among HIV-exposed infants \[[@CIT0036]\], and the availability of alternatives to RTV-boosted PIs in pregnancy, further study is necessary to understand the role of RTV boosting, and to identify the safest most effective cART regimens for HIV-positive women.
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